Acetazolamide in X-linked Retinoschisis
The effect of Acetazolamide on visual acuity, retinal thickness and macular cyst size in patients with X-linked retinoschisis
The University of Sydney
30 participants
Jun 21, 2010
Interventional
Conditions
Summary
X-linked retinoschisis is a genetic eye disorder characterised by abnormal splitting of the retina, resulting in a loss of vision. Currently there is no treatment available for X-linked retinoschisis. However, an improvement in sight has been reported following the use of topical and oral acetazolamide in people with X-linked retinoschisis. Hence, the objective of this study is to investigate whether oral acetazolamide improves the sight of people with X-linked retinoschisis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral acetazolamide 200mg twice a day >60kg or 125mg twice <60kg. Participants allocated to the acetazolamide/placebo study arm will receive acetazolamide first, followed by placebo, and vice versa in the placebo/acetazolamide. The duration of acetazolamide will be three months. The mode of administration is oral capsule. Cross over occurs at 3 months following first dose of treatment. Measurements at are done at 0, 3 and 6months. Hence no "wash-out" period is required.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000476033